Education
About Us
Working with TipRanks
Follow Us
Shilpa Medicare Limited (IN:SHILPAMED)
:SHILPAMED
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹501.60
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹63.49B
Enterprise Value₹69.24B
Total Cash (Recent Filing)₹535.50M
Total Debt (Recent Filing)₹5.93B
Price to Earnings (P/E)35.2
Beta0.97
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)2.28
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.70
Price to Sales (P/S)4.98
P/FCF Ratio-57.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.9
Revenue Forecast (FY)₹14.68B
Bulls Say, Bears Say
Bulls Say
Oncology & Complex Therapies FocusA strategic focus on oncology and other complex/specialty therapies creates durable competitive advantages: higher technical barriers, specialized regulatory pathways, and stickier customer relationships. This positioning supports premium pricing, long-term contracts and sustainable revenue streams.
Healthy Revenue Growth And MarginsConsistent top-line expansion alongside very strong gross margins indicates core product economics are solid and scalable. Even with moderate net margins, sustained revenue growth and high gross margins underpin durable profitability potential as the company scales and leverages fixed-cost absorption.
Improved Leverage And Strong Equity BaseMarkedly lower leverage and a high equity ratio provide long-term financial stability and flexibility. Reduced debt burden lowers interest risk and supports capital allocation for R&D or capacity expansion without jeopardizing solvency, improving resilience across business cycles.
Bears Say
Declining Operational EfficiencyA large fall in EBIT margin signals rising operating costs or lower operating leverage that can erode sustainable profitability. Unless cost structure or pricing is addressed, margin deterioration can persist and limit the company's ability to invest sustainably in R&D, capacity, or commercialization.
Negative Free Cash Flow ConversionNegative free cash flow despite stable operating cash flow points to heavy capital spending and weak profit-to-cash conversion. This strains liquidity and constrains reinvestment or deleveraging options, making growth and compliance investments dependent on external funding or slower organic cash build.
Low Returns On EquityDespite balance-sheet strength, low ROE indicates limited returns relative to capital employed. Modest net margins and headroom in operational performance mean capital may not generate robust shareholder returns, potentially limiting long-term value creation absent efficiency or product-mix improvements.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹501.60 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹63.49B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is May 21, 2026 which is in 62 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Feb 06, 2026. The company reported ₹2.28 earnings per share for the quarter, missing the consensus estimate of ₹2.8 by -₹0.52.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹2.28 in its last earnings report, missing expectations of ₹2.8. Following the earnings report the stock price went down -0.663%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―